On October 16, 2025 4SC AG (4SC, FSE Prime Standard: VSC) reported its Q3-Report 2025, presenting all material developments up to 30 September 2025, as well as the Company’s current outlook. The full report is available for download on 4SC’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Development of cash balance in Q3 2025 and financial forecast
As of 30 September 2025, 4SC holds cash balance/funds of €4,742 thousand as compared to €8,311 thousand as of 31 December 2024. The Management Board believes that the Company’s available cash and cash equivalents are sufficient to either:

in combination with a successful completion of the capital increase, result in sufficient cash for a transitional period to allow the Company at least until the end of 2026 to find a new business (as described in the invitation to the Company’s most recent AGM on 19 September 2025), or
cover the projected costs for an orderly liquidation if this could be completed by the end of Q1 2027. In the event of the Company being liquidated, the Management Board expects that 4SC will, at best, be able to repay a portion of the outstanding subordinated shareholder loans with no liquidation surplus for distribution to 4SC’s shareholders.

(Press release, 4SC, OCT 16, 2025, View Source [SID1234656711])